Graphite pulls off $238M IPO to sketch out path to clinic for gene-editing sickle cell treatment
In less than a year, Graphite Bio has sped from series A to Wall Street welcome as it rustles up capital to fund gene-editing treatments for sickle cell disease, an immune system disorder and Gaucher disease.